HEALTH

Clif Bar adds two flavors to its Luna Protein line

BY Michael Johnsen

EMERYVILLE, Calif. — Clif Bar on Tuesday announced two new flavors to its Luna Protein line — lemon vanilla and chocolate coconut almond. Lemon vanilla is the first Luna Protein bar without a chocolate coating.

“We realize that women are constantly on-the-go and may not have time to sit down and enjoy a protein-filled meal; they need a go-to snack that is nutritious and will keep them satiated,” said Tara DelloIacono-Thies, manager of nutrition strategy for Luna. “This is where Luna Protein comes in. We want women to have a nourishing and tasty option when they need it," she said. 

 

“The amount of protein women need depends on their activity level,” DelloIacono-Thies said. “I recommend women use the following basic formula to determine how much protein they should have each day to keep them going strong:"

  • Spends most the day sitting: Weight in pounds x 0.4 = grams of protein/day;
  • Physically demanding job and regularly active: Weight in pounds x 0.6 = grams of protein/day;
  • Competitive athlete: Weight in pounds x 0.75 = grams of protein/day.

The Luna Protein line first launched in 2010 to help women more easily fit protein into their diet. With Luna Protein Lemon Vanilla and Chocolate Coconut Almond, Luna continues its dedication to provide women with a wide array of snacks that have the nutrition they need in the flavors they crave.

The new Luna Protein bars will sell for a suggested retail price of $1.39.

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

NAD refers ad claims made by Coorga Nutraceuticals for its Grey Defense dietary supplements to FTC

BY Michael Johnsen

NEW YORK — The National Advertising Division on Tuesday referred advertising claims made by Coorga Nutraceuticals Corp. for its Grey Defense dietary supplements to the Federal Trade Commission.

NAD is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus.

NAD had requested substantiation for advertising claims that included “Reverse Grey Hair in 6 Months”; “Try Grey Defence Xtreme for 6 months, if the results don’t amaze, we’ll give you your money back”; “Grey Defence is a super-premium dietary supplement that is formulated to assist the body in reversing gray hair due to oxidative stress”; and “Grey Defence neutralizes hydrogen peroxide on contact, helping to slow, stop and reverse grey hair due to oxidative stress.”

The company, in response to NAD’s inquiry, declined to participate in the self-regulatory process. The advertiser noted that its decision was rooted in its concern about publicly disclosing the research upon which the company relies to support its advertising claims.

NAD was disappointed that the advertiser declined to participate in the self-regulatory process, the agency noted. In light of the advertiser’s position, NAD, pursuant to Section 2.9 of the NAD/NARB Procedures, referred this matter to the FTC for possible law enforcement action.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

FDA recommends health professionals prescribe no more than 325 mg of acetaminophen per dose

BY Michael Johnsen

SILVER SPRING, Md. — The Food and Drug Administration on Tuesday recommended healthcare professionals discontinue prescribing and dispensing prescription combination drug products that contain more than 325 mg of acetaminophen per tablet, capsule or other dosage unit. 

There are no available data to show that taking more than 325 mg of acetaminophen per dosage unit provides additional benefit that outweighs the added risks for liver injury, the agency noted. Further, limiting the amount of acetaminophen per dosage unit will reduce the risk of severe liver injury from inadvertent acetaminophen overdose, which can lead to liver failure, liver transplant and death. 

"We recommend that health care providers consider prescribing combination drug products that contain 325 mg or less of acetaminophen. We also recommend that when a pharmacist receives a prescription for a combination product with more than 325 mg of acetaminophen per dosage unit that they contact the prescriber to discuss a product with a lower dose of acetaminophen," the agency stated. "A two tablet or two capsule dose may still be prescribed, if appropriate. In that case, the total dose of acetaminophen would be 650 mg (the amount in two 325 mg dosage units). When making individual dosing determinations, health care providers should always consider the amounts of both the acetaminophen and the opioid components in the prescription combination drug product." 

In January 2011 the FDA asked manufacturers of prescription combination drug products containing acetaminophen to limit the amount of acetaminophen to no more than 325 mg in each tablet or capsule by January 14, 2014. "We requested this action to protect consumers from the risk of severe liver damage which can result from taking too much acetaminophen. This category of prescription drugs combines acetaminophen with another ingredient intended to treat pain (most often an opioid), and these products are commonly prescribed to consumers for pain, such as pain from acute injuries, post-operative pain or pain following dental procedures," the FDA noted.

More than half of manufacturers have voluntarily complied with the request, FDA reported. However, some prescription combination drug products containing more than 325 mg of acetaminophen per dosage unit remain available. "In the near future we intend to institute proceedings to withdraw approval of prescription combination drug products containing more than 325 mg of acetaminophen per dosage unit that remain on the market," the agency stated. 

Acetaminophen is also widely used as an over-the-counter pain and fever medication, and is often combined with other ingredients, such as cough and cold ingredients. The FDA plans to address OTC acetaminophen products in another regulatory action.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?